210 related articles for article (PubMed ID: 16193096)
21. Insulin glulisine complementing basal insulins: a review of structure and activity.
Becker RH
Diabetes Technol Ther; 2007 Feb; 9(1):109-21. PubMed ID: 17316105
[TBL] [Abstract][Full Text] [Related]
22. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus.
Ristic S; Bates PC
Diabetes Technol Ther; 2003; 5(1):57-66. PubMed ID: 12725708
[TBL] [Abstract][Full Text] [Related]
23. Micro- and macrovascular outcomes in Type 2 diabetic patients treated with insulin glulisine or human regular insulin: a retrospective database analysis.
Kress S; Kostev K; Dippel FW; Giani G; Rathmann W
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):821-9. PubMed ID: 22578200
[TBL] [Abstract][Full Text] [Related]
24. Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 diabetes: a randomized double-blind study.
Meyer C; Boron A; Plummer E; Voltchenok M; Vedda R
Diabetes Care; 2010 Dec; 33(12):2496-501. PubMed ID: 20805258
[TBL] [Abstract][Full Text] [Related]
25. Insulin analogues in the management of diabetes.
Vázquez-Carrera M; Silvestre JS
Methods Find Exp Clin Pharmacol; 2004; 26(6):445-61. PubMed ID: 15349139
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous insulin: pharmacokinetic variability and glycemic variability.
Guerci B; Sauvanet JP
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S7-4S24. PubMed ID: 16389894
[TBL] [Abstract][Full Text] [Related]
27. [The new insulins].
Krzentowski G
Rev Med Brux; 2005 Sep; 26(4):S241-5. PubMed ID: 16240869
[TBL] [Abstract][Full Text] [Related]
28. A review of types 1 and 2 diabetes mellitus and their treatment with insulin.
Salsali A; Nathan M
Am J Ther; 2006; 13(4):349-61. PubMed ID: 16858171
[TBL] [Abstract][Full Text] [Related]
29. Insulin lispro: new preparation. Faster acting.
Prescrire Int; 1998 Jun; 7(35):67-8. PubMed ID: 10342918
[TBL] [Abstract][Full Text] [Related]
30. Advantage of insulin glulisine over regular insulin in patients with type 2 diabetes and severe renal insufficiency.
Urata H; Mori K; Emoto M; Yamazaki Y; Motoyama K; Morioka T; Fukumoto S; Koyama H; Shoji T; Ishimura E; Inaba M
J Ren Nutr; 2015 Mar; 25(2):129-34. PubMed ID: 25238698
[TBL] [Abstract][Full Text] [Related]
31. Insulin lispro: a fast-acting insulin analog.
Noble SL; Johnston E; Walton B
Am Fam Physician; 1998 Jan; 57(2):279-86, 289-92. PubMed ID: 9456992
[TBL] [Abstract][Full Text] [Related]
32. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes.
Rave K; Klein O; Frick AD; Becker RH
Diabetes Care; 2006 Aug; 29(8):1812-7. PubMed ID: 16873785
[TBL] [Abstract][Full Text] [Related]
33. Insulin glulisine for continuous subcutaneous insulin infusion in pediatric type 1 diabetes.
Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
Pediatr Int; 2017 May; 59(5):647-649. PubMed ID: 28544684
[TBL] [Abstract][Full Text] [Related]
34. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
[TBL] [Abstract][Full Text] [Related]
35. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes.
Hoogma RP; Schumicki D
Horm Metab Res; 2006 Jun; 38(6):429-33. PubMed ID: 16823727
[TBL] [Abstract][Full Text] [Related]
36. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations.
Muchmore DB; Vaughn DE
J Diabetes Sci Technol; 2010 Mar; 4(2):419-28. PubMed ID: 20307403
[TBL] [Abstract][Full Text] [Related]
37. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
[TBL] [Abstract][Full Text] [Related]
38. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
Burge MR; Waters DL; Holcombe JH; Schade DS
J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
[TBL] [Abstract][Full Text] [Related]
39. Reducing hypoglycaemia with insulin analogues.
Heller S
Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S31-6. PubMed ID: 12174321
[TBL] [Abstract][Full Text] [Related]
40. [New developments in the treatment and monitoring of type 1 diabetes mellitus].
Otto-Buczkowska E; Jarosz-Chobot P; Tucholski K
Endokrynol Pol; 2008; 59(3):246-53. PubMed ID: 18615401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
